Personal Capital Advisors Corp decreased its position in Allergan PLC. (NYSE:AGN) by 5.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,701 shares of the company’s stock after selling 151 shares during the period. Personal Capital Advisors Corp’s holdings in Allergan PLC. were worth $657,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Israel Discount Bank of New York bought a new position in shares of Allergan PLC. during the first quarter worth $988,000. Trust Co. of Vermont raised its position in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after buying an additional 1,109 shares during the period. Capital Planning Advisors LLC raised its position in shares of Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock worth $878,000 after buying an additional 1,625 shares during the period. First Long Island Investors LLC bought a new position in shares of Allergan PLC. during the first quarter worth $4,826,000. Finally, Rehmann Capital Advisory Group raised its position in shares of Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock worth $425,000 after buying an additional 237 shares during the period. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Shares of Allergan PLC. (NYSE:AGN) traded down 0.85% during midday trading on Wednesday, hitting $228.48. 1,999,187 shares of the company were exchanged. The stock has a market cap of $76.38 billion, a PE ratio of 6.96 and a beta of 1.16. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The stock’s 50-day moving average is $245.03 and its 200-day moving average is $238.77.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the prior year, the company posted $3.35 EPS. The business’s revenue was up 8.8% on a year-over-year basis. Equities research analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is 9.95%.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/personal-capital-advisors-corp-has-657000-stake-in-allergan-plc-agn/1495769.html.

A number of brokerages have weighed in on AGN. Argus reiterated a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a report on Monday. UBS AG reiterated an “outperform” rating and issued a $275.00 price target on shares of Allergan PLC. in a report on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and issued a $278.00 price target (up previously from $273.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. BidaskClub lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Eight investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $275.49.

In other news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.